Skip to main content

Advertisement

SpringerLink
Log in

Low-dose nivolumab induced durable complete response in relapsed primary central nervous system diffuse large B cell lymphoma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G, International Extranodal Lymphoma Study Group (IELSG) (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol 4(11):e510–e523

    Article  PubMed  Google Scholar 

  2. Illerhaus G, Schorb E, Kasenda B (2018) Novel agents for primary central nervous system lymphoma: evidence and perspectives. Blood 132(7):681–688

    Article  CAS  PubMed  Google Scholar 

  3. Grommes C, DeAngelis LM (2017) Primary CNS lymphoma. J Clin Oncol 35(21):2410–2418

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA (2016) Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127(7):869–881

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27(4):450–461

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, Armand P, Rodig SJ, Shipp MA (2017) PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood 129(23):3071–3073

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hwang YY, Khong PL, Kwong YL (2017) Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma. Ann Hematol 96(7):1219–1220

    Article  PubMed  Google Scholar 

  8. Chan TSY, Sim JPY, Kwong YL (2017) Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation. Ann Hematol 96(9):1569–1572

    Article  CAS  PubMed  Google Scholar 

  9. Chan TSY, Li J, Loong F, Khong PL, Tse E, Kwong YL (2018) PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety. Ann Hematol 97(1):193–196

    Article  CAS  PubMed  Google Scholar 

  10. Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069–1086

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Queen Mary Hospital, Pokfulm Road, Hong Kong, China

    Thomas S. Y. Chan, Yok-Lam Kwong & Eric Tse

  2. Department of Diagnostic Radiology, Queen Mary Hospital, Hong Kong, Hong Kong

    Pek-Lan Khong

  3. Department of Pathology, Queen Mary Hospital, Hong Kong, Hong Kong

    Rex Au-Yeung

Authors
  1. Thomas S. Y. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pek-Lan Khong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rex Au-Yeung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yok-Lam Kwong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eric Tse
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

T.S.Y. Chan: treated the patient and wrote and approved the manuscript

P.L. Khong: performed the radiodiagnostics and wrote and approved the manuscript

R. Au-Yeung: performed the histopathologic diagnosis and wrote and approved the manuscript

Y.L. Kwong: treated the patient and wrote and approved the manuscript

E. Tse: treated the patient and wrote and approved the manuscript

Corresponding author

Correspondence to Yok-Lam Kwong.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Not applicable.

Informed consent

Patient gave informed consent to treatment.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chan, T.S.Y., Khong, PL., Au-Yeung, R. et al. Low-dose nivolumab induced durable complete response in relapsed primary central nervous system diffuse large B cell lymphoma. Ann Hematol 98, 2227–2230 (2019). https://doi.org/10.1007/s00277-019-03758-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03758-z

Search

Navigation